Employing “electronic nose” (eNose) technology early during treatment can accurately identify patients with advanced non-small cell lung cancer (NSCLC) who respond to immunotherapy, according to research published in Lung Cancer. The technology can allow for noninvasive, low-cost identification of responders early on, which could save patients from ineffective treatment, “thereby preventing...
treatment News
PARIS – ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a...
NAPLES, Fla. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that the Company has received approval from the Israeli Ministry of Health to begin the Phase 1/2 portion of its study of its lead asset, EV101,...
SAN MARINO — Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval,...
REYKJAVIK, Iceland – EpiEndo Pharmaceuticals (www.epiendo.com), a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, announced today that the first subjects have been dosed in the Company’s first-in-human phase I clinical trial of its lead candidate, EP395, at the Medicines Evaluation Unit (MEU) in Manchester, UK...
New York, NY – Epithelioid sarcoma, a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors, which affect children, have long been difficult to treat. But the outlook for people with these subtypes of soft tissue sarcoma brightened in 2020 when the Food and Drug Administration approved a targeted therapy called tazemetostat (Tazverik™) for certain...
New Haven, Conn. — Yale researchers have identified a drug target that may alleviate joint degeneration associated with osteoarthritis, a debilitating condition that afflicts as many as 30 million people in the United States alone, which they report on Jan. 3 in the journal Nature. Pain relievers and lifestyle changes, such as exercise...
SHANGHAI & SUZHOU, China – EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced dose administration for the first patient in a Phase 1/2 clinical trial of EMB-02, a bispecific antibody targeting PD-1 and LAG-3, in patients with advanced solid tumors, as well as in a...
CAMBRIDGE, Mass. – Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EZM0414, the Company’s novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment...
LONDON, England & BASEL, Switzerland — Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced successful completion of Good Manufacturing Practice (“GMP”) manufacturing of MOv18 IgE, Epsilogen’s...